nach oben

Drug Safety

Erschienen in:

01.06.2003 | Leading Article

Medication Errors Caused by Confusion of Drug Names

verfasst von: Dr James M. Hoffman, Susan M. Proulx

Erschienen in: Drug Safety | Ausgabe 7/2003

Einloggen, um Zugang zu erhalten

Abstract

Many drug names can look or sound like other drug names, which leads to confusion and potentially harmful medication errors. While various types of drug names exist, brand (proprietary) names are most commonly confused. Examples of the numerous drug names that have been confused because they look and/or sound similar include Celebrex® (celecoxib), Cerebyx® (fosphenytoin), and Celexa® (citalopram). Factors such as poor handwriting and clinical similarity may exacerbate the problem. This problem can be alleviated through actions by regulatory agencies, pharmaceutical manufacturers, healthcare professionals, and patients. To address the problem, significant changes in the pharmaceutical regulatory process have occurred in the US and Europe.

Use of brand names is for identification purposes only and does not imply endorsement.

Leape LL. A systems analysis approach to medical error. In: Cohen MR, editor. Medication errors. Washington, DC: American Pharmaceutical Association, 1999: 2.1–2.14

Kohn LT, Corrigan JM, Donaldson MS, editors. To err is human: building a safer health system. Washington, DC: National Academy Press, 1999

Williams E. Institute for Safe Medication Practices. Editorial response to pharmacist workload articles [online]. Available from URL: http://www.ismp.org/Pages/editorial.html [Accessed 2002 Mar 3]

Starr CH. When drug names spell trouble. Drug Topics 2000 May 15; 144(10): 49–58

United States Pharmacopoeia Convention. Stop, look, and listen! United States Pharmacopoeia Qual Rev 1995; 49

Cohen MR. Drug product characteristics that foster drug-use-system errors. Am J Health Syst Pharm 1995; 52: 395–9PubMed

Lesar TS, Briceland L, Stein DS. Factors related to errors in medication prescribing. JAMA 1997 Jan 22; 277(4): 312–7PubMedCrossRef

Kenagy JW, Stein GC. Naming, labeling, and packaging of pharmaceuticals. Am J Health-Syst Pharm 2001; 58: 2033–41PubMed

Sentinel event alert: look-alike, sound-alike drug names [online]. Available from URL: http://www.jcaho.org/about+us/news+letters/sentinel+event+alert/sea_19.htm [Accessed 2002 Dec 13]

10.

Sentinel events [online]. Available from URL: http://www.jcaho.org/about+us/news+letters/sentinel+event+alert/perspectives+article.htm [Accessed 2002 Dec 14]

11.

Davis NM, Cohen MR, Teplitsky B. Look-alike and sound-alike drug names: the problem and the solution. Hosp Pharm 1992 Feb; 27: 95–8, 102–5, 108–10PubMed

12.

Aronson JK. Confusion over similar drug names problems and solutions. Drug Saf 1995; 12(3): 155–60PubMedCrossRef

13.

Teplitsky B. Confusing names of drugs [letter]. JAMA 1969 Mar 31; 207(13): 2440PubMed

14.

Solomon KJ. Medication errors from similar trademarks [letter]. JAMA 1978 Mar 20; 239(12): 1130PubMedCrossRef

15.

Wittaker RL. Confused drug names [letter]. Ann Intern Med 1980 Dec; 93(6): 933

16.

Huminer D, Dux S, Rosenfeld JB, et al. Inadvertent sulfonylurea-induced hypoglycemia: a dangerous, but preventable condition. Arch Intern Med 1989 Aug; 149: 1890–2PubMedCrossRef

17.

Shumak SL, Corenblum B, Steiner G. Recurrent hypoglycemia secondary to drug-dispensing error. Arch Intern Med 1991 Sep; 151: 1877–8PubMedCrossRef

18.

Fine SN, Eisdorfer RM, Miskovitz PF, et al. Losec or Lasix [letter]. N Engl J Med 1990 Jun 7; 322: 1674PubMed

19.

Hooper PL, Tello RJ, Burstein PJ, et al. Pseudoinsulinoma: the Diamox-Diabinese switch [letter]. N Engl J Med 1990 Aug 16; 323: 488PubMed

20.

Hoffman JP. More on ‘Losec or Lasix’ [letter]. N Engl J Med 1990 Nov 15; 323: 1428PubMed

21.

Kurth MC, Langston JW, Tetrud JW. “Stelazine” versus “Selegiline”: a hazard in prescription writing [letter]. N Engl J Med 1990 Dec 20; 323: 1776PubMed

22.

Huseby JS, Anderson P. Confusion about drug names. N Engl J Med 1991 Aug 22; 325(8): 588–9PubMedCrossRef

23.

Fraterrigo CC, Frangella GM. The “Z” word [letter]. Am J Hosp Pharm 1994 Jan 15; 51: 235PubMed

24.

Anon. Confusion of drug names signalled [letter]. CMAJ 1995 Jun 1; 152 (11): 1749

25.

Costable JM, McKinley MJ. Prozac or prilosec for gastric ulcer [letter]. N Engl J Med 1996 Aug 22; 335(8): 600PubMedCrossRef

26.

Teplitsky B. Caution: 1000 drugs whose names look or sound alike. Pharm Times 1978 Jan; 44: 41–3

27.

McNulty H, Spurr P. Drug names that look or sound alike [letter]. BMJ 1979 Oct 6; 2(6194): 836PubMedCrossRef

28.

Davis NM. Drug names that look and sound alike. Hosp Pharm 1999; 34: 1160–2, 1164–6, 1169–70, 1173–4, 1177–8

29.

Lambert BL, Chang KY, Lin SJ. Effect of orthographic and phonological similarity on false recognition of drug names. Soc Sci Med 2001; 52: 1843–57PubMedCrossRef

30.

Boring D. More names. Mod Drug Discov 2000 Oct; 3(8): 35–6

31.

Boring D. The development and adoption of nonproprietary, established, and proprietary names for pharmaceuticals. Drug Inf J 1997; 31: 621–34CrossRef

32.

Boring DL. The CDER labeling and nomenclature committee: Structure, function, and process. Drug Inf J 1997; 31: 7–11CrossRef

33.

World Health Organization. International nonproprietary names: revised procedure [online]. Available from URL: http://www.who.int/gb/EB_WHA/PDF/EB110/eeb1103.pdf [Accessed 2003 Mar 19]

34.

Friedmanis R. editor. USAN Handbook, 5th ed. Chicago (IL); American Medical Association, 1999

35.

British Pharmacopoeia. British approved names [online]. Available from URL: http://www.pharmacopoeia.org.uk/british.cfm [Accessed 2003 Mar 19]

36.

British Pharmacopoeia. British approved names: guiding principles [online]. Available from URL: http://www.pharmacopoeia.org.uk/guiding.cfm [Accessed 2003 Mar 19]

37.

Fleeger CA, editor. USP dictionary of USAN and international drug names. Rockville (MD); US Pharmacopeia, 1997

38.

Cohen MR, DiDomizio G. Key challenges in global branding. World Markets Series: Healthcare and Pharmaceutical Briefing. 2000: 28–30

39.

Zoeller J. Searle weighs Celebrex name change: new cox-2 has been confused with other similarly-named drugs. Am Druggist 1999 May; 216(5): 15

40.

Dispensing errors alert [online]. Available from URL: http://www.fda.gov/medwatch/safety/2000/lamict.htm [Accessed 2002 Mar 3]

41.

Smetzer J, Cohen MR, editors. Safety briefs. Institute for Safe Medication Practices (ISMP) Medication Safety Alert 1999 Oct 6; 4(20): 1–3

42.

Smetzer J, Cohen MR, editors. Safety Briefs. Institute for Safe Medication Practices (ISMP) Medication Safety Alert 1999 Sept 8; 4(18): 1

43.

Mitka M. What’s in a (drug) name? plenty! JAMA 1999 Oct 20; 282(15): 1409–10PubMedCrossRef

44.

Amrinone to become inamrinone based upon USP Nomenclature Committee and USAN council decisions. Available from URL: http://www.usp.org/aboutusp/releases/2000/pr_2000-05.htm [Accessed 2002 Mar 03]

45.

Cohen MR, Anderson RW, Attilio RM, et al. Preventing medication errors in cancer chemotherapy. Am J Health Syst Pharm 1996; 53: 737–46PubMed

46.

Mahmud A, Holquist C, Phillips J. Stemming drug errors from abbreviations [online]. Available from URL: http://www.fda.gov/cder/drug/mederrors/nameAbbreviations.pdf. [Accessed 2002 Dec 16]

47.

Schwab M, Oetzel C, Morike K, et al. Using trade names: a risk factor for accidental drug overdose. Arch Intern Med 2002; 162: 1065–6PubMedCrossRef

48.

Phillips J. The name game: new realities at FDA. Pharm Executive 2000 Jul, 9

49.

Holquist C, Phillips J. How FDA reviews drug names [online]. Available from URL: http://www.fda.gov/cder/drug/MedErrors/reviewDrugNames.pdf [Accessed 2002 Dec 15]

50.

Palmer C. OPDRA Consult #00-0046 [online]. Available from URL: http://www.fda.gov/cder/drug/infopage/unithroid/optrare.pdf [Accessed 2002 Dec 16]

51.

Committee for Proprietary Medicinal Products (CPMP). Revised guidance paper on the acceptability of tradenames for human medicinal products processed through the centralised procedure [online]. Available from URL: http://www.emea.eu.int/pdfs/human/regaffair/032898en.pdf [accessed 2002 Mar 03]

52.

Lambert BL. Predicting look- and sound-alike medication errors. Am J Health Syst Pharm 1997; 54: 1161–71PubMed

53.

Lambert BL, Lin S-J, Gandhi SK, et al. Similarity as a risk factor in drug name confusion errors: the look-alike (orthographic) and sound-alike (phonological) model. Med Care 1999; 37: 1214–25PubMedCrossRef

54.

Cohen MR. Preventing medication errors related to prescribing. In: Cohen MR, editor. Medication errors. Washington, DC: American Pharmaceutical Association, 1999: 8.1–8.23

55.

Bates DW, Leape LL, Cullen DJ, et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA 1998; 280: 1311–6PubMedCrossRef

56.

Bates DW, Teich JM, Lee J, et al. The impact of computerized physician order entry on medication error prevention. JAMA 1999; 6: 313–21

57.

Institute for Safe Medication Practices (ISMP). A call to action: eliminate handwritten prescriptions within 3 years. Huntingdon Hall (PA), 2000 Apr

58.

Schiff GD, Rucker D. Computerized prescribing: building the electronic infrastructure for better medication usage. JAMA 1998; 279: 1024–9PubMedCrossRef

59.

Leape LL, Berwick DM, Bates DW. What practices will most improve safety? Evidence-based medicine meets patient safety. JAMA 2002; 288: 501–7PubMedCrossRef

Titel: Medication Errors Caused by Confusion of Drug Names
verfasst von: Dr James M. Hoffman
Susan M. Proulx
Publikationsdatum: 01.06.2003
Verlag: Springer International Publishing
Erschienen in: Drug Safety / Ausgabe 7/2003
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI: https://doi.org/10.2165/00002018-200326070-00001

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2003

Important Drug Safety Information on the Internet

Benefits and Risks of Pharmacological Treatments for Essential Tremor

Cardiovascular Safety of Sildenafil

Benefit-Risk Assessment of Antileukotrienes in the Management of Asthma